市場調查報告書

口腔粘膜炎(OM):市場洞察,流行病學,市場預測 ∼2027年

Oral Mucositis - Market Insight, Epidemiology and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 736691
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
口腔粘膜炎(OM):市場洞察,流行病學,市場預測 ∼2027年 Oral Mucositis - Market Insight, Epidemiology and Market Forecast - 2028
出版日期: 2019年01月01日內容資訊: 英文 100 Pages
簡介

主要8個國家(美國,英國,德國,法國,義大利,西班牙,日本,中國)的口腔粘膜炎(OM)的確診患者數在2016年為533萬3,193人,市場規模估計為6億3,880萬美元。

本報告提供全球口腔粘膜炎(OM)的相關調查,疾病概要,患者背景,主要8個國家等級、各風險因子的診斷數,各治療藥物的市場規模的變化與預測(今後10年份),已上市藥及新藥概要,診斷指南,市場規模,市場成長要素、障礙,競爭情形等調查總括性彙整。

目錄

第1章 重要洞察

第2章 報告概要

第3章 口腔粘膜炎(OM)市場:概要

  • 市場佔有率(成果值)
  • 市場佔有率(預測值)

第4章 口腔粘膜炎(OM):疾病背景和概要

  • 簡介
  • 症狀
  • 病因
  • 口腔粘膜炎的危險因素
  • 病理生理學
  • 診斷
  • 評估尺度
  • WHO的口腔粘膜炎的判斷標準
  • 國立癌症研究所(NCI)的不良事件共通用語標準(CTCAE)
  • 參考文獻

第5章 流行病學和患者人口

  • 主要的觀察
  • 主要8個國家口腔粘膜炎(OM)的診斷數

第6章 口腔粘膜炎(OM)的流行病學:各國

  • 美國
    • 前提和根據
    • 診斷數
    • 診斷數:各等級
    • 診斷數:各風險因子
  • 歐洲主要5個國家
    • 德國
      • 診斷數
      • 診斷數:各等級
      • 診斷數:各風險因子
    • 法國
      • 診斷數
      • 診斷數:各等級
      • 診斷數:各風險因子
    • 義大利
      • 診斷數
      • 診斷數:各等級
      • 診斷數:各風險因子
    • 西班牙
      • 診斷數
      • 診斷數:各等級
      • 診斷數:各風險因子
    • 英國
      • 診斷數
      • 診斷數:各等級
      • 診斷數:各風險因子
  • 日本
    • 診斷數
    • 診斷數:各等級
    • 診斷數:各風險因子
  • 中國
    • 診斷數
    • 診斷數:各等級
    • 診斷數:各風險因子

第7章 現行的治療方法

  • 化療誘發性口腔粘膜炎的治療和預防
  • MASCC/ISOO指南的推薦事項
  • 接受造血幹細胞移植(HSCT)的患者治療和預防的選項
  • 放射治療誘發性口腔粘膜炎的治療和預防
  • 口腔粘膜炎及口腔併發症的治療
  • UKOMiC(英國的口腔粘膜炎 - 癌症群組)
  • 診斷,治療,跟蹤的ESMO臨床實踐指南

第8章 未滿足需求

第9章 已上市藥

  • Key Cross Competition
  • Gelclair:Helsinn Healthcare
    • 藥品概要
    • 法規的里程碑
    • 產品簡介
  • Caphosol:EUSA Pharma/Canbridge Life Sciences
  • Episil:Solasia Pharma/Camurus AB
  • MuGard:Access Pharmaceuticals
  • Kepivance:Swedish Orphan Biovitrum AB

第10章 新藥

  • 重點交叉競爭
  • Dusquetide:Soligenix Inc.
    • 藥品概要
    • 法規的里程碑
    • 臨床開發
    • 安全性和有效性
    • 產品的簡介
  • EC-18:Enzychem Lifesciences Corporation
  • Rebamipide:大塚製藥
  • RRx-001:EpicentRx
  • AG013:Oragenics Inc
  • GC4419:Galera Therapeutics
  • SAMITAL: Indena S.p.A
  • Mucomel:Spherium Biomed
  • Brilacidin:Innovation Pharmaceuticals
  • Validive:Monar Therapeutics
  • Folotyn and Leucovorin:Spectrum Pharmaceuticals

第11章 主要觀察

第12章 主要8個國家的市場規模

第13章 美國市場預測

  • 美國的市場規模
    • 總市場規模
    • 市場規模:各治療藥物

第14章 市場預測歐洲5個國家

  • 德國的市場規模
    • 總市場規模
    • 市場規模:各治療藥物
  • 法國的市場規模
    • 總市場規模
    • 市場規模:各治療藥物
  • 義大利的市場規模
    • 總市場規模
    • 市場規模:各治療藥物
  • 西班牙的市場規模
    • 總市場規模
    • 市場規模:各治療藥物
  • 英國的市場規模
    • 總市場規模
    • 市場規模:各治療藥物

第15章 日本市場預測

  • 日本的市場規模
    • 總市場規模
    • 市場規模:各治療藥物

第16章 中國市場預測

  • 中國的市場規模
    • 總市場規模
    • 市場規模:各治療藥物

第17章 市場成長要素

第18章 市場障礙

第19章 DelveInsight的服務內容

第20章 附錄

  • 調查方法

第21章 免責聲明

第22章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0154

DelveInsight's "Oral Mucositis - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Oral Mucositis epidemiology and market outlook for the 7MM.

Markets Covered

  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2016-2028

Oral Mucositis Understanding and Treatment Algorithm

The market report provides the overview of the Oral Mucositis by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Oral Mucositis Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Oral Mucositis in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Oral Mucositis Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Oral Mucositis Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Oral Mucositis market.

Oral Mucositis Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Oral Mucositis Report Insights

  • Patient Population in Oral Mucositis
  • Therapeutic Approaches in Oral Mucositis
  • Oral Mucositis Pipeline Analysis
  • Oral Mucositis Market Size and Trends
  • Oral Mucositis Market Opportunities
  • Impact of upcoming Therapies in Oral Mucositis

Oral Mucositis Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Oral Mucositis Report Assessment

  • Current Treatment Practices in Oral Mucositis
  • Unmet Needs in Oral Mucositis
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • The report will help to develop Business Strategies by understanding the trends shaping and driving the Oral Mucositis market
  • Organize sales and marketing efforts by identifying the best opportunities for Oral Mucositis market
  • To understand the future market competition in the Oral Mucositis market.

Table of Contents

1. Report Introduction

2. Oral Mucositis Market Overview at a Glance

  • 2.1. Market Share Distribution of Oral Mucositis in 2016
  • 2.2. Market Share Distribution of Oral Mucositis in 2028

3. Disease Background and Overview: Oral Mucositis

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Diagnosis
  • 3.7. Treatment

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent/ Incident Patient Population of Oral Mucositis in 7MM
  • 4.3. Total Prevalent Patient Population of Oral Mucositis in 7MM - By Countries

5. Epidemiology of Oral Mucositis by Countries

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Prevalent/Incident Cases of the Oral Mucositis
    • 5.1.3. Sub-Type Specific cases of the Oral Mucositis *
    • 5.1.4. Sex- Specific Cases of the Oral Mucositis *
    • 5.1.5. Diagnosed Cases of the Oral Mucositis
    • 5.1.6. Treatable Cases of the Oral Mucositis
  • 5.2. EU5
  • 5.3. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Prevalent/Incident Cases of the Oral Mucositis
    • 5.4.3. Sub-Type Specific cases of the Oral Mucositis *
    • 5.4.4. Sex- Specific Cases of the Oral Mucositis *
    • 5.4.5. Diagnosed Cases of the Oral Mucositis
    • 5.4.6. Treatable Cases of the Oral Mucositis
  • 5.5. France
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Prevalent/Incident Cases of the Oral Mucositis
    • 5.5.3. Sub-Type Specific cases of the Oral Mucositis *
    • 5.5.4. Sex- Specific Cases of the Oral Mucositis *
    • 5.5.5. Diagnosed Cases of the Oral Mucositis
    • 5.5.6. Treatable Cases of the Oral Mucositis
  • 5.6. Italy
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Prevalent/Incident Cases of the Oral Mucositis
    • 5.6.3. Sub-Type Specific cases of the Oral Mucositis *
    • 5.6.4. Sex- Specific Cases of the Oral Mucositis *
    • 5.6.5. Diagnosed Cases of the Oral Mucositis
    • 5.6.6. Treatable Cases of the Oral Mucositis
  • 5.7. Spain
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Prevalent/Incident Cases of the Oral Mucositis
    • 5.7.3. Sub-Type Specific cases of the Oral Mucositis *
    • 5.7.4. Sex- Specific Cases of the Oral Mucositis *
    • 5.7.5. Diagnosed Cases of the Oral Mucositis
    • 5.7.6. Treatable Cases of the Oral Mucositis
  • 5.8. United Kingdom
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Prevalent/Incident Cases of the Oral Mucositis
    • 5.8.3. Sub-Type Specific cases of the Oral Mucositis *
    • 5.8.4. Sex- Specific Cases of the Oral Mucositis *
    • 5.8.5. Diagnosed Cases of the Oral Mucositis
    • 5.8.6. Treatable Cases of the Oral Mucositis
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Prevalent/Incident Cases of the Oral Mucositis
    • 5.9.3. Sub-Type Specific cases of the Oral Mucositis *
    • 5.9.4. Sex- Specific Cases of the Oral Mucositis *
    • 5.9.5. Diagnosed Cases of the Oral Mucositis
    • 5.9.6. Treatable Cases of the Oral Mucositis

6. Current Treatment & Medical practices

  • 6.1. Treatment Algorithm
  • 6.2. Treatment Guidelines

7. Unmet Needs of the Oral Mucositis

8. Marketed Therapies

  • 8.1. Drug A: Company 1
    • 8.1.1. Drug Description
    • 8.1.2. Mechanism of Action
    • 8.1.3. Regulatory Milestones
    • 8.1.4. Advantages & Disadvantages
    • 8.1.5. Product Profile
  • 8.2. Drug B: Company 2
    • 8.2.1. Drug Description
    • 8.2.2. Mechanism of Action
    • 8.2.3. Regulatory Milestones
    • 8.2.4. Advantages & Disadvantages
    • 8.2.5. Product Profile

9. Pipeline Therapies - At a glance

10. Key Cross Competition

11. Emerging Therapies for Oral Mucositis

  • 11.1. Drug C: Company 3
    • 11.1.1. Drug Description
    • 11.1.2. Clinical Trials Details
    • 11.1.3. Safety and Efficacy Profile
    • 11.1.4. Advantages & Disadvantages
    • 11.1.5. Pipeline Development Activities
    • 11.1.6. Product Profile
  • 11.2. Drug D: Company 4
    • 11.2.1. Drug Description
    • 11.2.2. Clinical Trials Details
    • 11.2.3. Safety and Efficacy Profile
    • 11.2.4. Advantages & Disadvantages
    • 11.2.5. Pipeline Development Activities
    • 11.2.6. Product Profile

12. Oral Mucositis : 7MM Market Analysis

  • 12.1. 7MM Market Size of Oral Mucositis
  • 12.2. 7MM Percentage Share of drugs marketed for Oral Mucositis
  • 12.3. 7MM Market Sales of Oral Mucositis by Products

13. Oral Mucositis : Country-Wise Market Analysis

  • 13.1. United States
    • 13.1.1. Market Size of Oral Mucositis in United States
    • 13.1.2. Percentage Share of drugs marketed for Oral Mucositis in United States
    • 13.1.3. Market Sales of Oral Mucositis by Products in United States
    • 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.2. EU-5
    • 13.2.1. Germany
      • 13.2.1.1. Market Size of Oral Mucositis in Germany
      • 13.2.1.2. Percentage Share of drugs marketed for Oral Mucositis in Germany
      • 13.2.1.3. Market Sales of Oral Mucositis by Products in Germany
      • 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.2. France
      • 13.2.2.1. Market Size of Oral Mucositis in France
      • 13.2.2.2. Percentage Share of drugs marketed for Oral Mucositis in France
      • 13.2.2.3. Market Sales of Oral Mucositis by Products in France
      • 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.3. Italy
      • 13.2.3.1. Market Size of Oral Mucositis in Italy
      • 13.2.3.2. Percentage Share of drugs marketed for Oral Mucositis in Italy
      • 13.2.3.3. Market Sales of Oral Mucositis by Products in Italy
      • 13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.4. Spain
      • 13.2.4.1. Market Size of Oral Mucositis in Spain
      • 13.2.4.2. Percentage Share of drugs marketed for Oral Mucositis in Spain
      • 13.2.4.3. Market Sales of Oral Mucositis by Products in Spain
      • 13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
    • 13.2.5. United Kingdom
      • 13.2.5.1. Market Size of Oral Mucositis in United Kingdom
      • 13.2.5.2. Percentage Share of drugs marketed for Oral Mucositis in United Kingdom
      • 13.2.5.3. Market Sales of Oral Mucositis by Products in United Kingdom
      • 13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
  • 13.3. Japan
    • 13.3.1. Market Size of Oral Mucositis in Japan
    • 13.3.2. Percentage Share of drugs marketed for Oral Mucositis in Japan
    • 13.3.3. Market Sales of Oral Mucositis by Products in Japan
    • 13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology

  • 17.1. Sources

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Indication Specific

List of Tables

  • Table 1: Total Prevalent/Incident Cases of the Oral Mucositis in 7MM
  • Table 2: Total Prevalent/Incident Cases of the Oral Mucositis in 7MM by Countries
  • Table 3: Prevalent/Incident Cases of the Oral Mucositis in United States (2016-2028)
  • Table 4: Sub-Type Specific cases of the Oral Mucositis in United States (2016-2028)
  • Table 5: Sex- Specific Cases of the Oral Mucositis in United States (2016-2028)
  • Table 6: Diagnosed Cases of the Oral Mucositis in United States (2016-2028)
  • Table 7: Treatable Cases of the Oral Mucositis in United States (2016-2028)
  • Table 8: Prevalent/Incident Cases of the Oral Mucositis in Germany (2016-2028)
  • Table 9: Sub-Type Specific cases of the Oral Mucositis in Germany (2016-2028)
  • Table 10: Sex- Specific Cases of the Oral Mucositis in Germany (2016-2028)
  • Table 11: Diagnosed Cases of the Oral Mucositis in Germany (2016-2028)
  • Table 12: Treatable Cases of the Oral Mucositis in Germany (2016-2028)
  • Table 13: Prevalent/Incident Cases of the Oral Mucositis in France (2016-2028)
  • Table 14: Sub-Type Specific cases of the Oral Mucositis in France (2016-2028)
  • Table 15: Sex- Specific Cases of the Oral Mucositis in France (2016-2028)
  • Table 16: Diagnosed Cases of the Oral Mucositis in France (2016-2028)
  • Table 17: Treatable Cases of the Oral Mucositis in France (2016-2028)
  • Table 18: Prevalent/Incident Cases of the Oral Mucositis in Italy (2016-2028)
  • Table 19: Sub-Type Specific cases of the Oral Mucositis in Italy (2016-2028)
  • Table 20: Sex- Specific Cases of the Oral Mucositis in Italy (2016-2028)
  • Table 21: Diagnosed Cases of the Oral Mucositis in Italy (2016-2028)
  • Table 22: Treatable Cases of the Oral Mucositis in Italy (2016-2028)
  • Table 23: Prevalent/Incident Cases of the Oral Mucositis in Spain (2016-2028)
  • Table 24: Sub-Type Specific cases of the Oral Mucositis in Spain (2016-2028)
  • Table 25: Sex- Specific Cases of the Oral Mucositis in Spain (2016-2028)
  • Table 26: Diagnosed Cases of the Oral Mucositis in Spain (2016-2028)
  • Table 27: Treatable Cases of the Oral Mucositis in Spain (2016-2028)
  • Table 28: Prevalent/Incident Cases of the Oral Mucositis in UK (2016-2028)
  • Table 29: Sub-Type Specific cases of the Oral Mucositis in UK (2016-2028)
  • Table 30: Sex- Specific Cases of the Oral Mucositis in UK (2016-2028)
  • Table 31: Diagnosed Cases of the Oral Mucositis in UK (2016-2028)
  • Table 32: Treatable Cases of the Oral Mucositis in UK (2016-2028)
  • Table 33: Prevalent/Incident Cases of the Oral Mucositis in Japan (2016-2028)
  • Table 34: Sub-Type Specific cases of the Oral Mucositis in Japan (2016-2028)
  • Table 35: Sex- Specific Cases of the Oral Mucositis in Japan (2016-2028)
  • Table 36: Diagnosed Cases of the Oral Mucositis in Japan (2016-2028)
  • Table 37: Treatable Cases of the Oral Mucositis in Japan (2016-2028)
  • Table 38: Marketed Therapies
  • Table 39: Emerging Therapies
  • Table 40: Key Cross Competition
  • Table 41:7MM- Market Size of Oral Mucositis in USD MM (2016-2028)
  • Table 42:7MM- Market Share Oral Mucositis by Therapies in USD MM (2016-2028)
  • Table 43:7MM- Market Sales of Oral Mucositis by Therapies in USD MM (2016-2028)
  • Table 44: United States-Market Size of Oral Mucositis in USD MM (2016-2028)
  • Table 45: United States-Market Share Oral Mucositis by Therapies in USD MM (2016-2028)
  • Table 46: United States-Market Sales of Oral Mucositis by Therapies in USD MM (2016-2028)
  • Table 47: Germany-Market Size of Oral Mucositis in USD MM (2016-2028)
  • Table 48: Germany-Market Share Oral Mucositis by Therapies in USD MM (2016-2028)
  • Table 49: Germany-Market Sales of Oral Mucositis by Therapies in USD MM (2016-2028)
  • Table 50: France-Market Size of Oral Mucositis in USD MM (2016-2028)
  • Table 51: France-Market Share Oral Mucositis by Therapies in USD MM (2016-2028)
  • Table 52: France-Market Sales of Oral Mucositis by Therapies in USD MM (2016-2028)
  • Table 53: Italy-Market Size of Oral Mucositis in USD MM (2016-2028)
  • Table 54: Italy-Market Share Oral Mucositis by Therapies in USD MM (2016-2028)
  • Table 55: Italy-Market Sales of Oral Mucositis by Therapies in USD MM (2016-2028)
  • Table 56: Spain-Market Size of Oral Mucositis in USD MM (2016-2028)
  • Table 57: Spain-Market Share Oral Mucositis by Therapies in USD MM (2016-2028)
  • Table 58: Spain-Market Sales of Oral Mucositis by Therapies in USD MM (2016-2028)
  • Table 59:UK-Market Size of Oral Mucositis in USD MM (2016-2028)
  • Table 60:UK-Market Share Oral Mucositis by Therapies in USD MM (2016-2028)
  • Table 61:UK-Market Sales of Oral Mucositis by Therapies in USD MM (2016-2028)
  • Table 62: Japan-Market Size of Oral Mucositis in USD MM (2016-2028)
  • Table 63: Japan-Market Share Oral Mucositis by Therapies in USD MM (2016-2028)
  • Table 64: Japan-Market Sales of Oral Mucositis by Therapies in USD MM (2016-2028)

List of Figures

  • Figure 1: Total Prevalent/Incident Cases of the Oral Mucositis in 7MM
  • Figure 2: Total Prevalent/Incident Cases of the Oral Mucositis in 7MM by Countries
  • Figure 3: Prevalent/Incident Cases of the Oral Mucositis in United States (2016-2028)
  • Figure 4: Sub-Type Specific cases of the Oral Mucositis in United States (2016-2028)
  • Figure 5: Sex- Specific Cases of the Oral Mucositis in United States (2016-2028)
  • Figure 6: Diagnosed Cases of the Oral Mucositis in United States (2016-2028)
  • Figure 7: Treatable Cases of the Oral Mucositis in United States (2016-2028)
  • Figure 8: Prevalent/Incident Cases of the Oral Mucositis in Germany (2016-2028)
  • Figure 9: Sub-Type Specific cases of the Oral Mucositis in Germany (2016-2028)
  • Figure 10: Sex- Specific Cases of the Oral Mucositis in Germany (2016-2028)
  • Figure 11: Diagnosed Cases of the Oral Mucositis in Germany (2016-2028)
  • Figure 12: Treatable Cases of the Oral Mucositis in Germany (2016-2028)
  • Figure 13: Prevalent/Incident Cases of the Oral Mucositis in France (2016-2028)
  • Figure 14: Sub-Type Specific cases of the Oral Mucositis in France (2016-2028)
  • Figure 15: Sex- Specific Cases of the Oral Mucositis in France (2016-2028)
  • Figure 16: Diagnosed Cases of the Oral Mucositis in France (2016-2028)
  • Figure 17: Treatable Cases of the Oral Mucositis in France (2016-2028)
  • Figure 18: Prevalent/Incident Cases of the Oral Mucositis in Italy (2016-2028)
  • Figure 19: Sub-Type Specific cases of the Oral Mucositis in Italy (2016-2028)
  • Figure 20: Sex- Specific Cases of the Oral Mucositis in Italy (2016-2028)
  • Figure 21: Diagnosed Cases of the Oral Mucositis in Italy (2016-2028)
  • Figure 22: Treatable Cases of the Oral Mucositis in Italy (2016-2028)
  • Figure 23: Prevalent/Incident Cases of the Oral Mucositis in Spain (2016-2028)
  • Figure 24: Sub-Type Specific cases of the Oral Mucositis in Spain (2016-2028)
  • Figure 25: Sex- Specific Cases of the Oral Mucositis in Spain (2016-2028)
  • Figure 26: Diagnosed Cases of the Oral Mucositis in Spain (2016-2028)
  • Figure 27: Treatable Cases of the Oral Mucositis in Spain (2016-2028)
  • Figure 28: Prevalent/Incident Cases of the Oral Mucositis in UK (2016-2028)
  • Figure 29: Sub-Type Specific cases of the Oral Mucositis in UK (2016-2028)
  • Figure 30: Sex- Specific Cases of the Oral Mucositis in UK (2016-2028)
  • Figure 31: Diagnosed Cases of the Oral Mucositis in UK (2016-2028)
  • Figure 32: Treatable Cases of the Oral Mucositis in UK (2016-2028)
  • Figure 33: Prevalent/Incident Cases of the Oral Mucositis in Japan (2016-2028)
  • Figure 34: Sub-Type Specific cases of the Oral Mucositis in Japan (2016-2028)
  • Figure 35: Sex- Specific Cases of the Oral Mucositis in Japan (2016-2028)
  • Figure 36: Diagnosed Cases of the Oral Mucositis in Japan (2016-2028)
  • Figure 37: Treatable Cases of the Oral Mucositis in Japan (2016-2028)
  • Figure 38: Marketed Therapies
  • Figure 39: Emerging Therapies
  • Figure 40: Key Cross Competition
  • Figure 41:7MM- Market Size of Oral Mucositis in USD MM (2016-2028)
  • Figure 42:7MM- Market Share Oral Mucositis by Therapies in USD MM (2016-2028)
  • Figure 43:7MM- Market Sales of Oral Mucositis by Therapies in USD MM (2016-2028)
  • Figure 44: United States-Market Size of Oral Mucositis in USD MM (2016-2028)
  • Figure 45: United States-Market Share Oral Mucositis by Therapies in USD MM (2016-2028)
  • Figure 46: United States-Market Sales of Oral Mucositis by Therapies in USD MM (2016-2028)
  • Figure 47: Germany-Market Size of Oral Mucositis in USD MM (2016-2028)
  • Figure 48: Germany-Market Share Oral Mucositis by Therapies in USD MM (2016-2028)
  • Figure 49: Germany-Market Sales of Oral Mucositis by Therapies in USD MM (2016-2028)
  • Figure 50: France-Market Size of Oral Mucositis in USD MM (2016-2028)
  • Figure 51: France-Market Share Oral Mucositis by Therapies in USD MM (2016-2028)
  • Figure 52: France-Market Sales of Oral Mucositis by Therapies in USD MM (2016-2028)
  • Figure 53: Italy-Market Size of Oral Mucositis in USD MM (2016-2028)
  • Figure 54: Italy-Market Share Oral Mucositis by Therapies in USD MM (2016-2028)
  • Figure 55: Italy-Market Sales of Oral Mucositis by Therapies in USD MM (2016-2028)
  • Figure 56: Spain-Market Size of Oral Mucositis in USD MM (2016-2028)
  • Figure 57: Spain-Market Share Oral Mucositis by Therapies in USD MM (2016-2028)
  • Figure 58: Spain-Market Sales of Oral Mucositis by Therapies in USD MM (2016-2028)
  • Figure 59:UK-Market Size of Oral Mucositis in USD MM (2016-2028)
  • Figure 60:UK-Market Share Oral Mucositis by Therapies in USD MM (2016-2028)
  • Figure 61:UK-Market Sales of Oral Mucositis by Therapies in USD MM (2016-2028)
  • Figure 62: Japan-Market Size of Oral Mucositis in USD MM (2016-2028)
  • Figure 63: Japan-Market Share Oral Mucositis by Therapies in USD MM (2016-2028)
  • Figure 64: Japan-Market Sales of Oral Mucositis by Therapies in USD MM (2016-2028)
Back to Top